Transcript BRCC Research Method and Approach

EXPLORING THE INTERPLAY
BETWEEN BUSINESS REGULATION
& CORPORATE CONDUCT (BRCC)
Rijit Sengupta
Jaipur, 13th April 2012
1. INTRODUCTION TO
RESEARCH METHODOLOGY
BRCC Research
Research Outline (BRCC Project)
3





Definition of Corporate Conduct – National
Voluntary Guidelines on Social, Environmental &
Economic Responsibilities of Business (NVG)
NVG: 9 Principles of Business Responsibility (BR)
Sectors: Pharmaceuticals and Private Healthcare
Value-Chain approach (Sectors) – critical BR issues
Identification of Research Problems
Research Problems (BRCC Project)
4

What is the level of adverse environmental impact (especially
in terms of pollution) from Pharmaceutical companies in the
state? Why have the available regulatory safeguards not
worked in places where impacts were found to be significant?
What should be done to make these regulations work, so that
such adverse environmental impacts may be minimised?

What is the current status of incentives (cuts/commissions)
provided by Pharmaceutical companies to Doctors and
Chemists in the state? What impact does it have on ‘Rational
Use of Drugs’? Why have these incentives continued to be
provided by the companies, in spite of regulatory safeguards
being in place? What can be done to ensure that companies
undertake their marketing activities keeping in view the
principle of ‘Rational Use of Drugs’?
Research Problems (BRCC Project)
5

How prevalent is the act of cuts/commissions to doctors
(individuals/in hospitals) among diagnostic service providers
in the state? Why have these cuts/commissions to doctors
existed in spite of regulatory safeguards in place? How to
combat the situation? What have been the efforts of hospital
associations and other such collectives to deal with the
problem? What are the regulatory barriers, if any?

What is the current status of bio-medical waste management
practices being followed by hospitals and diagnostic service
providers in the state? If the situation is problematic, why is it
so – in spite of regulatory safeguards? How can the situation
be corrected? What have been the steps taken up by the
hospital associations/industry bodies to deal with the
problem? What are the good practices? What are the drivers of
good practices and how can these be scaled up or replicated?
Research Problems (BRCC Project)
6

What is the extent to which standard treatment protocol is
being followed in the state by (private) healthcare providers? If
there are deviations, what are the reasons for these and other
instances of non-compliance? How can it be ensured that
hospitals promote alignment with standard treatment
protocol? Are there adequate measures undertaken by the
healthcare providers to respect the diagnosis and treatment
related queries of clients (patients and their attendants etc.)?
Are there any self-regulatory mechanisms in place?
Field-work in States
7


Fact Finding Mission in States
(Meeting Stakeholders, Ground Truth Verification, Initial
Contacts, Data Sources, etc.)
Key Research Output
Regulation
Enforcement
Critical Factors




Guidance Note
Targeted Respondents
Survey Method and Tools
Draft State-level reports
Outcome
(Corporate
Conduct)
Targeted SHs Vs Survey Tools
8




INTERVIEWS: Government Deptt, Regulators, Business
Associations, Sectoral Associations, Stakeholders
(CSO/Academia, Media)
SAMPLE SURVEY: Pharma Firms, Private Hospitals, Medical
Representatives
PRESCRIPTION ANALYSIS: Behaviour of doctors in Private
Hospitals
FGDs: Medical Representatives, Media
2. ITEMS & APPROACH
BRCC Field-work (States)
Approach to Undertaking Field-work
10







Stage-wise fieldwork: Stages I to III
Partners Workshop I: mid-April 2012 for Stage I
Partners Workshop II: end-May 2012 for Stages II & III
Survey Tools and Methodology: CUTS & Partners
State-level Reports: ToR by CUTS and guidance; drafting by
partners; review by CUTS & Advisors
Approaching respondents for interviews in State: CUTS and
Partners
Meeting and feedback from national level experts: CUTS
3. SURVEY OF PHARMA
FIRMS
BRCC Field-work (States)
Approach to Sample Selection in States
PHARMACEUTICALS
12





Selection of districts in each state with maximum concentration
of Pharma Firms
Total no. of firms in the selected districts, including distribution
(i.e., no of Bulk and Formulations)
10% of total to be selected
Proportion of Bulk & Formulations same as their distribution in
these districts
Large and SMEs to be selected
Questionnaire
13
•
•
•
•
•
•
•
•
Some element of flexibility to align questionnaires better to
state is allowed (to be communicated to CUTS)
Pre-Testing of questionnaire in States (partners)
Set up the meeting by writing to the Firm
Indicate the purpose is for research and policy advocacy
Facilitate more comprehensive approach to BR
Administer the questionnaire by giving opportunity to
respondent to speak as much
Gather both quantitative & qualitative info
Undertake analysis with guidance from CUTS
14
Thank You!
www.cuts-ccier.org/BRCC